ConductScience.org, home

Paper36958796

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.

Smith RM and 43 others. Ann Rheum Dis, 2023. Cited by 107 papers, by iCite.

Cite this record

ConductScience Library. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Papers, record 36958796. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36958796

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
PubMed
Journal
Ann Rheum Dis
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, Equivalence Trial
PubMed
Citations, by iCite
107
iCite
Relative citation ratio, by iCite
14.1
iCite
Revised in PubMed
2026-05-18
PubMed

Authors44

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Smith RMRona Mhttps://orcid.org/0000-0002-7438-5156
2Jones RBRachel B
3Specks UUlrich
4Bond SSimon
5Nodale MMariannahttps://orcid.org/0000-0002-0333-8918
6Al-Jayyousi RReem
7Andrews JJacqueline
8Bruchfeld AAnnette
9Camilleri BBrian
10Carette SSimon
11Cheung CKChee Kay
12Derebail VVimal
13Doulton TTim
14Ferraro AAlastair
15Forbess LLindsy
16Fujimoto SShouichihttps://orcid.org/0000-0002-0025-4030
17Furuta SShunsukehttps://orcid.org/0000-0003-2482-2685
18Gewurz-Singer OOra
19Harper LLorrainehttps://orcid.org/0000-0003-1343-9234
20Ito-Ihara TToshiko

Source PubMed

See all 44 authorsDownload CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AzathioprineMajor topic
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMajor topic
Humans
Rituximab
Immunosuppressive Agents
Recurrence
Remission Induction
Treatment Outcome
Cyclophosphamide
Antibodies, Antineutrophil Cytoplasmic

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Wellcome TrustUnited KingdomPubMedPubMed
19706Versus ArthritisUnited KingdomPubMedPubMed
U54 AR057319NIAMS NIH HHSUnited StatesU54AR057319PubMed and NIHNIH RePORTER
U54 RR019497NCRR NIH HHSUnited StatesU54RR019497PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01697267Rituximab Vasculitis Maintenance StudyDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in37523707In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.https://conductscience.org/library/papers/37523707

Source PubMed

Download CSV of comments and corrections

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115673801Etanercept plus standard therapy for Wegener's granulomatosis.N Engl J Med2005https://conductscience.org/library/papers/15673801PubMed
235317410Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.Lancet Rheumatol2022https://conductscience.org/library/papers/35317410PubMed
335714496Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy.J Autoimmun2022https://conductscience.org/library/papers/35714496PubMed
435115385Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.RMD Open2022https://conductscience.org/library/papers/35115385PubMed
521953279Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum2012https://conductscience.org/library/papers/21953279PubMed
634781162Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.J Autoimmun2021https://conductscience.org/library/papers/34781162PubMed
734977602Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.Lancet Rheumatol2022https://conductscience.org/library/papers/34977602PubMed
8230451702012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.Arthritis Rheum2013https://conductscience.org/library/papers/23045170PubMed
923902481Efficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med2013https://conductscience.org/library/papers/23902481PubMed
1020647199Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med2010https://conductscience.org/library/papers/20647199PubMed
1119454608Assessment of damage in vasculitis: expert ratings of damage.Rheumatology (Oxford)2009https://conductscience.org/library/papers/19454608PubMed
1233141217Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.Rheumatology (Oxford)2021https://conductscience.org/library/papers/33141217PubMed
1332053298Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.N Engl J Med2020https://conductscience.org/library/papers/32053298PubMed
1419451574Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.Ann Intern Med2009https://conductscience.org/library/papers/19451574PubMed
1512840090A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.N Engl J Med2003https://conductscience.org/library/papers/12840090PubMed
1628270229Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.Trials2017https://conductscience.org/library/papers/28270229PubMed
1722729997Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum2012https://conductscience.org/library/papers/22729997PubMed
1825372085Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.N Engl J Med2014https://conductscience.org/library/papers/25372085PubMed
1911318006A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).Arthritis Rheum2001https://conductscience.org/library/papers/11318006PubMed
204157287Long-term follow-up study of periarteritis nodosa.Am J Med1967https://conductscience.org/library/papers/4157287PubMed

See all 29 referencesDownload CSV of references

Cited by69

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.

PMIDTitleJournalYearIn PapersSource
42955334Immunosuppressive management of ANCA-associated glomerulonephritis in children.Pediatr Nephrol2026https://conductscience.org/library/papers/42955334PubMed
42851467Targeting tissue immune memory in chronic-remitting autoimmune kidney diseases: current concepts and future therapies.Clin Kidney J2026https://conductscience.org/library/papers/42851467PubMed
42761370Clinical scenarios of suboptimal response to rituximab in relapsing ANCA-associated vasculitis.Front Med (Lausanne)2026https://conductscience.org/library/papers/42761370PubMed
42743142Clinical outcomes after relapse during rituximab-based maintenance in ANCA-associated vasculitis: A single-center retrospective cohort study.PLoS One2026https://conductscience.org/library/papers/42743142PubMed
42720689Multi-database pharmacovigilance identifies disproportionate reporting of hepatobiliary events with avacopan: an integrative study with network pharmacology and interpretable machine learning.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42720689PubMed
42649433From ANCA-mediated vascular injury to coronary microvascular and myocardial involvement in granulomatosis with polyangiitis: an immunocardiology perspective.Rheumatol Int2026https://conductscience.org/library/papers/42649433PubMed
42614134
Immunoglobulin replacement therapy in antineutrophil cytoplasmic antibody-associated vasculitis with rituximab-associated hypogammaglobulinemia: infection outcomes and disease course in a retrospective cohort.
Front Nephrol2026https://conductscience.org/library/papers/42614134PubMed
42553115BAFF and APRIL signaling in the B-cell lineage: implications for the pathogenesis of ANCA-associated vasculitis.Front Immunol2026https://conductscience.org/library/papers/42553115PubMed
42532981Biosimilar Rituximab in ANCA-Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study.ACR Open Rheumatol2026https://conductscience.org/library/papers/42532981PubMed
42512795Advances in the Diagnosis, Treatment and Prognosis of ANCA-Associated Glomerulonephritis.Medicina (Kaunas)2026https://conductscience.org/library/papers/42512795PubMed
42482905ANCA-associated vasculitis: a phase-oriented therapeutic framework from immunopathology to precision treatment.Front Med (Lausanne)2026https://conductscience.org/library/papers/42482905PubMed
42391608Mechanisms, clinical manifestations and management of cardiovascular diseases in ANCA-associated vasculitis.Rheumatology (Oxford)2026https://conductscience.org/library/papers/42391608PubMed
42342286No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study.RMD Open2026https://conductscience.org/library/papers/42342286PubMed
41866438Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.Clin Rev Allergy Immunol2026https://conductscience.org/library/papers/41866438PubMed
41803922
Predictors of glucocorticoid-free clinical remission in patients with newly diagnosed microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study using a nationwide registry in Japan (J-CANVAS).
Arthritis Res Ther2026https://conductscience.org/library/papers/41803922PubMed
41675526Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines.Can J Kidney Health Dis2026https://conductscience.org/library/papers/41675526PubMed
41439239Shifting Sands or ANCA-ed in Place? The Epidemiology of ANCA-Associated Vasculitis over 2 Decades at a Large Tertiary Centre.Glomerular Dis2026https://conductscience.org/library/papers/41439239PubMed
41412975Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab.Arthritis Rheumatol2026https://conductscience.org/library/papers/41412975PubMed
41345710Maternal-fetal outcomes and therapeutic strategies in pregnancies complicated by Takayasu arteritis: a comprehensive analysis.Arthritis Res Ther2025https://conductscience.org/library/papers/41345710PubMed
41324350Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement.Am J Respir Crit Care Med2025https://conductscience.org/library/papers/41324350PubMed

See all 69 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CMPK151727PubTator's text mininghttps://conductscience.org/library/genes/51727NCBI Gene
MPO4353PubTator's text mininghttps://conductscience.org/library/genes/4353NCBI Gene
PRTN35657PubTator's text mininghttps://conductscience.org/library/genes/5657NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
RITUXIMABCHEMBL1201576Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201576ChEMBL
AZATHIOPRINECHEMBL1542Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1542ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36958796

GET https://conductscience.org/api/papers/v1/36958796/authors?page=2